Please login to the form below

Not currently logged in
Email:
Password:

peglispro

This page shows the latest peglispro news and features for those working in and with pharma, biotech and healthcare.

Lilly's Lantus 'follow-on' approved in the US

Lilly's Lantus 'follow-on' approved in the US

Approval is a boost to Lilly, which decided earlier this month to abandon development of another Lantus rival - insulin peglispro - after concluding data on a potential toxicity issue made the project

Latest news

  • Lilly says insulin peglispro too risky to pursue Lilly says insulin peglispro too risky to pursue

    Lilly says insulin peglispro too risky to pursue. Discontinues development of medicine once tipped as a diabetes blockbuster. ... Eli Lilly has decided to discontinue development of insulin peglispro, a drug once considered a potential blockbuster for

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    However, there was some good news for Novo Nordisk when it emerged Eli Lilly had delayed filings for its long-acting insulin peglispro candidate after a safety signal was seen in

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The company also released the results of five phase III studies of its long-acting insulin peglispro, which had a serious setback earlier this year when liver fat changes seen in ... However, some of the IMAGINE trials showed an increase in the liver

  • Sanofi wins European approval for Lantus follow-up Toujeo Sanofi wins European approval for Lantus follow-up Toujeo

    However, the company will have slightly longer to establish Toujeo than it originally expected after regulatory filings for Lilly's insulin peglispro were delayed recently due to safety concerns.

  • FDA starts review of Novo's refiled diabetes pair FDA starts review of Novo's refiled diabetes pair

    Until recently, additional competition was also looming in the form of Lilly's long-acting insulin peglispro, although that project has now been significantly delayed after fatty liver changes were seen

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics